TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
|Conference Call & Webcast Details|
|Date:||Tuesday, November 7|
|Time:||4:30pm Eastern Time|
|Replays, Available through November 21st:|
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates highly multiplexed molecular profiling of minute samples for next-generation sequencing, received its first US patent in 2014. Continuous improvements led to the 2017 launch of HTG’s new direct-target sequencing chemistry for DNA analysis offered in the company’s VERI/O services laboratory. Additional information is available at www.htgmolecular.com.
LifeSci Advisors, LLC
HTG Molecular Diagnostics
Source:HTG Molecular Diagnostics, Inc.